Electronic monitor, transdermal patches may be available by year 2000.

PIP: Sano Corp. of Miramar, Florida, has obtained an exclusive license with the Population Council for the North American rights to use the council's progestin, Nesterone, in transdermal patches for female contraception and hormone replacement therapy. The agreement also allows Sano to secure the exclusive, worldwide rights for the transdermal use of the council's patented, synthetic androgen, 7-alpha methyl-19-nortestosterone (MENT), for male contraception and the treatment of hypogonadism. Unilever of London has established Unipath Diagnostics Company in New York City to serve as the local base for the potential launch of the Unipath contraceptive system. Comprised of a small electronic monitor initialized the first day after the start of a woman's menstrual cycle, the device can objectively tell a woman upon which days it is safe to have unprotected sexual intercourse.

PMID: 12321210 [PubMed - indexed for MEDLINE]